Pages that link to "Q37629835"

The following pages link to Recent changes in the landscape of combination RAS blockade (Q37629835):

Displaying 15 items.

• Reducing cardiorenal risk through combination therapy with a direct renin inhibitor (Q26851307) (← links)
• Aliskiren and valsartan combination therapy for the management of hypertension (Q34139070) (← links)
• Tailored antihypertensive drug therapy prescribed to older women attenuates circulating levels of interleukin-6 and tumor necrosis factor-α (Q34977437) (← links)
• Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control (Q35210518) (← links)
• Steap4 attenuates high glucose and S100B-induced effects in mesangial cells (Q35695497) (← links)
• Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012 (Q36818863) (← links)
• Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends (Q37802083) (← links)
• The role of direct renin inhibition in clinical practice: focus on combination therapy (Q37918526) (← links)
• Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. (Q38041505) (← links)
• Oxidative stress in chronic vascular disease: From prediction to prevention. (Q38585518) (← links)
• Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats (Q47782437) (← links)
• Anti-stress and nootropic activity of drugs affecting the renin-angiotensin system in rats based on indirect biochemical evidence (Q50690842) (← links)
• Management of angiotensin-converting enzyme inhibitor-induced angioedema. (Q51512693) (← links)
• Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells (Q54640381) (← links)
• Identification and Inhibitory Properties of Multifunctional Peptides from Pea Protein Hydrolysate (Q85170526) (← links)